

BRCA2 Polyclonal Antibody

Catalog No. E-AB-40288

Note: Centrifuge before opening to ensure complete recovery of vial contents.


Description

Reactivity	Human,Rat
Immunogen	Recombinant Human Breast cancer type 2 susceptibility protein
Host	Rabbit
Isotype	IgG
Purification	Antigen Affinity Purification
Conjugation	Unconjugated
Buffer	PBS with 0.02% sodium azide,1% protective protein and 50% glycerol,pH7.4

Applications Recommended Dilution

WB	1:1000-1:3000
IHC	1:100-1:200
IF	1:100-1:400

Data




Western Blot analysis of Jurkat, MCF-7 and A431 cells using BRCA2 Polyclonal Antibody at dilution of 1:2000


Observed Mw:384 kDa
Calculated Mw:384 kDa



Western Blot analysis of HeLa cells using BRCA2 Polyclonal Antibody at dilution of 1:2000




Western Blot analysis of Rat testis using BRCA2 Polyclonal Antibody at dilution of 1:2000




Immunohistochemistry of paraffin-embedded Human colon using BRCA2 Polyclonal Antibody at dilution of 1:100

For Research Use Only



Immunohistochemistry of paraffin-embedded Human breast using BRCA2 Polyclonal Antibody at dilution of 1:100



Immunofluorescence analysis of U-2OS cells using BRCA2 Polyclonal Antibody at dilution of 1:100

Preparation & Storage

Storage Store at -20°C. Avoid freeze / thaw cycles.

Background

Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele.